Previous Article | Next Article ![]()
Infection and Immunity, July 2003, p. 4026-4033, Vol. 71, No. 7
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.7.4026-4033.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Dermatology Department, St. John's Institute of Dermatology, Guy's Hospital, Guy's, Kings and St. Thomas' Medical Schools, London, United Kingdom,1 Microbiology Department, Chiang-Mai Medical School, Chiang-Mai, Thailand,2 Department of Physiology and Biophysics,3 Department of Medicine,4 Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, New York5
Received 14 January 2003/ Returned for modification 27 February 2003/ Accepted 20 March 2003
|
|
|---|
|
|
|---|
Melanins are a ubiquitous class of biological pigments which play important roles throughout the plant and animal kingdoms (11). They are high-molecular-weight negatively charged pigments that are typically dark brown or black and are formed by the oxidative polymerization of phenolic and/or indolic compounds (1). In fungi melanins have attracted considerable interest as putative virulence factors, particularly in plant pathogens (19, 24); most of the latter produce dihydroxynaphthalene (DHN) melanin via a pathway involving a series of enzymes, including polyketide synthase and scytalone reductase (1).
In the human fungal pathogen Cryptococcus neoformans melanin is formed in the presence of exogenous dihydroxyphenolic compounds (12, 13, 34) by the action of a laccase, and it has been implicated in pathogenesis (2, 22, 27). Data suggesting that there is a possible link between melanization and pathogenesis has also been obtained for Aspergillus fumigatus (14, 30) and Exophilia dermatitidis (28). Melanization has also been identified in Histoplasma capsulatum (20) and Paracoccidioides brasiliensis (7). In S. schenckii it has been demonstrated that production of a melanin-like pigment occurs via the 1,8-DHN pentaketide pathway (25), and the pigment appears to protect conidia from oxidant damage and macrophage attack. In this study we attempted (i) to confirm that a melanin-like pigment is produced by conidia of S. schenckii and (ii) to determine whether S. schenckii can synthesize melanin or melanin-like compounds in the yeast phase by utilizing techniques developed to study and isolate melanin from other fungal pathogens.
|
|
|---|
Isolation and purification of conidium and yeast particles, scanning electron microscopy, transmission electron microscopy, and ESR spectroscopy. Melanin particles were isolated from pigmented conidia and yeast cells grown for 60 and 7 days, respectively, as previously described (7, 27). In brief, cells were collected by centrifugation and washed three times with phosphate-buffered saline (PBS) (0.1 M, pH 7.5) and then suspended in 1.0 M sorbitol-0.1 M sodium citrate (pH 5.5). Cells were then treated in turn with lysing enzymes (from Trichoderma harzianum; Sigma, Poole, Dorset, United Kingdom), 4 M guanidine thiocyanate (denaturant), and proteinase K (Roche Laboratories, Lewes, East Sussex, United Kingdom), (7, 27). The resultant material was then boiled in 6 M HCl, washed, and collected as previously described (7, 27). Scanning electron microscopy and transmission electron microscopy of melanin particles from both conidia and yeast cells of S. schenckii 16127 were then performed as previously described (27). Electron spin resonance (ESR) spectroscopy analyses were performed as previously described with melanin particles from both conidia and yeast cells by using a Gunn diode as the microwave source (5, 27).
Production of MAbs against S. schenckii yeast cell melanin. Monoclonal antibodies (MAbs) were generated against S. schenckii yeast cell melanin particles derived from yeast cell cultures grown in BHI broth. Briefly, adult female BALB/c mice received five intraperitoneal inoculations (at 2-week intervals) containing 300 µg of melanin particles made up in Freund's incomplete adjuvant (Difco, East Molesey, Surrey, United Kingdom). Polyclonal antibody responses against melanin were determined by an enzyme-linked immunosorbent assay ELISA (see below), and the spleen from the most responsive mouse was used to produce hybridomas by using the sp2/0 fusion partner (8, 9, 35).
ELISA.
Ninety-six-well ELISA plates (BDH, Poole, Dorset, United Kingdom) were used throughout this study for ELISA. Melanins from the following sources were suspended in distilled water at a concentration of 50 µg of melanin particles per well: S. schenckii conidia and yeast cells, Penicillium marneffei conidia, A. fumigatus conidia, Aspergillus niger conidia, C. neoformans yeast cells (all fungal melanin ghosts were produced as described above), synthetic melanin (Sigma), and Sepia melanin (Sigma). The plates were then left undisturbed for 3 days at room temperature to allow for evaporation prior to baking at 60°C for 1 h and were blocked overnight with 5% (wt/vol) bovine serum albumin (Sigma) at 4°C. The plates were washed with Tris-buffered saline containing Tween (0.05%, vol/vol), and MAbs (either the novel anti-S. schenckii melanin MAbs or MAb 6D2, produced against melanin from C. neoformans [26]) were added to the wells diluted 1:100 to 1:12,800 in PBS. The plates were incubated for 1.5 h at 37°C, washed as described above, and then probed with peroxidase-conjugated goat anti-mouse immunoglobulin M (IgM) (Jackson, West Grove, Pa.) at a dilution of 1:1,000 (incubated for 1.5 h at 37°C). Subsequently, o-phenylenediamine (Sigma) at a concentration of 20 µg per well was added, and the plates were left for 5 min in the dark to develop. Then 0.01 M sulfuric acid was added to stop the reaction, and 100 µl of liquid from each well was transferred to a fresh plate for reading with an ELISA reader (Ancos) at 490 nm against a 620-nm reference filter. The negative controls consisted of melanins incubated with MAb 5C11(µ
), which binds to lipoarabinomannan of mycobacteria (6) as the primary antibody, fluorescein isothiocyanate (FITC)-labeled antibody alone, and wells that did not contain melanin.
Immunofluorescence analysis of melanin expression.
Melanin particles derived from conidia and yeast cells (grown in BHI medium and minimal medium) were fixed onto 3-aminopropyltriethoxysilane-coated slides by evaporation at room temperature. The slides were then blocked with Superblock (Roche) overnight at 4°C. Slide cultures of S. schenckii mycelia were prepared as described previously and blocked as described above. All slides were then incubated for 2 h at 37°C with 10 µg of either the novel anti-S. schenckii melanin MAbs or melanin-binding MAb 6D2. After they were washed in PBS, the slides were then incubated in a 1:100 dilution of FITC-conjugated goat anti-mouse IgM (Jackson) for 2 h at 37°C and washed again in PBS. Finally, the slides were mounted with 0.1 M PBS and glycerol at a ratio of 1:1 and examined. The negative controls consisted of either the irrelevant antibody MAb 5C11(µ
) as the primary antibody or FITC-labeled antibody alone.
To determine whether sera from patients infected with S. schenckii contained anti-melanin antibodies, slides coated with yeast cell-derived melanin were incubated with human sera from Colombian patients with sporotrichosis (pretreatment) at dilutions of 1:10, 1:100, and 1:1,000 in 2% (wt/vol) bovine serum albumin for 1.5 h at 37°C. Informed consent was previously obtained from the patients. After PBS washes the slides were incubated with a 1:100 dilution of FITC-conjugated goat anti-human IgM (Jackson) for 1 h at 37°C. The slides were washed, mounted, and viewed as described above. Negative control sera (from normal, uninfected individuals) were also tested, and controls in which melanin was incubated with the conjugate alone were also included.
To examine in vivo expression of melanin, paraffin-embedded hamster testicular tissue infected with strain 16127 was sectioned. The paraffin was removed, and the sections were rehydrated, treated with 20 µg of proteinase K per ml for 1 h at room temperature, and then heated in 10 mM citric acid in a microwave for 5 min. Slides were incubated in Superblock blocking buffer overnight at 4°C. Melanin-binding MAbs at a dilution of 1:100 were added to the slides, which were then incubated at 37°C for 1 h. After washing, the slides were incubated with a 1:100 dilution of FITC-conjugated goat anti-mouse IgM (Jackson). The slides were washed and mounted as described above. The negative controls consisted of slides incubated with FITC-labeled antibody alone or the irrelevant antibody MAb 5C11(µ
). In addition, melanin particles were extracted from S. schenckii-infected paraffin-embedded hamster tissue by using the melanin isolation method described above and air dried onto 3-aminopropyltriethoxysilane-covered slides. The latter slides were then probed with the various anti-melanin MAbs and FITC-conjugated goat anti-mouse IgM as described above.
|
|
|---|
![]() View larger version (69K): [in a new window] |
FIG. 1. Scanning electron micrographs of S. schenckii conidia and yeast cells before and after treatment with enzymes, denaturant, and hot acid. (A and B) Conidia before and after treatment, respectively; (C and D) yeast cells grown in BHI broth before and after treatment, respectively; (E and F) yeast cells grown in minimal medium broth before and after treatment, respectively. Bars, 1 µm.
|
![]() View larger version (69K): [in a new window] |
FIG. 2. Transmission electron micrographs of S. schenckii conidium (A) and yeast cell grown in minimal medium (B), showing the outer melanin layer. Bars, 0.5 µm.
|
MAb production and ELISA reactivity.
A total of seven anti-S. schenckii melanin MAbs (all IgMs) were produced. These novel MAbs (designated MAbs 2G5, 7G10, 5B11, 8B5, 5D7, 7C5, and 4C11) all reacted with the diverse melanin particles tested, including commercial sources of the pigment (Fig. 3), as did the positive control MAb 6D2(µ
). Of the eight melanins tested, the highest optical densities were obtained when Sporothrix yeast cell melanin particles were used. The most reactive MAbs were MAbs 2G5 and 6D2. Negative control wells (wells without melanin, wells incubated with control MAb 5C11(µ
), or wells containing melanin but incubated without a primary antibody) were unreactive.
![]() View larger version (47K): [in a new window] |
FIG. 3. ELISA reactivities of the seven novel anti-S. schenckii melanin MAbs and of MAb 6D2 (produced against melanin from C. neoformans), diluted 1:100, with the following eight different types of melanins (50 µg/well): synthetic, Sepia, S. schenckii conidial (Sporo con), S. schenckii yeast cell (sporo yst), P. marneffei conidial (Pen Mar), A. fumigatus conidial (Asp fum), A. niger conidial (Asp nig), and C. neoformans yeast cell (Cryp neo). The negative control (neg) was wells incubated with MAb 5C11(µ ) in place of anti-melanin MAbs. OD, optical density.
|
) (data not shown).
![]() View larger version (116K): [in a new window] |
FIG. 4. Corresponding bright-field (A) and immunofluorescent (B) microscopic images of S. schenckii melanin particles from conidia and corresponding bright-field (C) and immunofluorescence (D) images of yeast cells grown in BHI broth after the preparations were reacted with anti-S. schenckii melanin MAb 7C5 (representative of a novel panel of MAbs). Bars, 10 µm.
|
) was used.
![]() View larger version (105K): [in a new window] |
FIG. 5. Corresponding bright-field (A) and immunofluorescent (B) microscopic images showing the labeling of S. schenckii yeast cells by MAb 2G7 (anti-S. schenckii melanin MAb) in a hamster testicle and corresponding bright-field (C) and immunofluorescent (D) microscopic images showing particles recovered from a hamster testicle (as described above) following treatment of the tissue with enzymes, denaturant, and hot acid, after preparations were reacted with anti-S. schenckii melanin MAb 7C5. The particles are similar in size and shape to S. schenckii yeast cells. Bars, 5 µm.
|
Reactivity of sera from humans infected with S. schenckii with melanin as determined by the immunofluorescent antibody test. Sera from Colombian patients infected with S. schenckii showed positive recognition of S. schenckii yeast cell-derived melanin particles when they were diluted 1:100, as determined by the immunofluorescent antibody test (Fig. 6). Sera from uninfected controls from Colombia and the United Kingdom showed no reactivity.
![]() View larger version (61K): [in a new window] |
FIG. 6. Corresponding bright-field (A) and immunofluorescent (B) microscopic images showing the labeling of melanin particles derived from S. schenckii yeast cells by pooled sera from patients with sporotrichosis. Preparations were diluted 1:100 with 2% bovine serum albumin. Bars, 10 µm.
|
|
|
|---|
In the present study we sought to confirm that melanin is produced by S. schenckii conidia. Our evidence that melanin is formed by S. schenckii conidia (which complements the data of Romero-Martinez et al. [25]) is as follows: (i) treatment of pigmented S. schenckii conidia with enzymes and chemicals resulted in isolation of black particles that were similar in size and shape to the original propagules, (ii) ESR spectroscopy analysis of pigmented conidium-derived particles showed the presence of a stable free radical compound consistent with melanin, and (iii) melanin-binding MAbs reacted with the cell surface of pigmented S. schenckii conidia grown in vitro and with the pigmented particles derived from these cells. In contrast, hyphal structures do not appear to be melanized, a pattern similar to the pattern seen in H. capsulatum and P. brasiliensis (7, 20). The conidia in these fungi probably have a dual role as agents of environmental dissemination and as infectious propagules, and as such the protection against environmental insults provided by melanization is likely to be an important attribute.
Using techniques that have been developed for the study of melanization in other pathogens (7, 20, 21), we also investigated melanization in the yeast phase of S. schenckii. For the first time, detailed evidence that melanin is produced by S. schenckii yeast cells was obtained, as follows: (i) treatment of wild-type yeast cells grown on BHI medium and minimal medium with enzymes, denaturant, and acid resulted in isolation of black particles that were similar in shape and size to the original yeast cells; (ii) ESR spectroscopy analysis of the yeast cell-derived particles indicated that a stable free radical compound consistent with melanin was present; (iii) melanin-binding MAbs reacted with the cell surfaces of yeast cells grown in vitro and with the pigmented particles derived from these cells; (iv) melanin-binding MAbs reacted with the cell wall of S. schenckii in infected hamster tissue; (v) we recovered melanin-like particles that were similar in size and shape to S. schenckii yeast cells from infected hamster tissue after enzymatic and chemical treatment and were also reactive with the melanin-binding MAbs; and (vi) sera from patients with sporotrichosis reacted with melanin particles derived from S. schenckii yeast cells. Together, these observations provide very good evidence that S. schenckii yeast cells can make melanin in vitro and in vivo. Several previous studies support the hypothesis that there is melanization by S. schenckii yeast cells. Thus, Staib et al. (29) found that some strains of S. schenckii grown on niger seed creatinine agar at 37°C produced brown pigment. In addition, Kwon-Chung et al. (18) demonstrated that the Masson-Fontana stain (which was originally used to delineate melanin production in C. neoformans) showed that there was a faint brown pigment in the walls of S. schenckii yeast cells.
The MAbs raised against the melanin particles derived from S. schenckii yeast cells represent the largest available panel of anti-melanin MAbs to date. Previously, MAbs have been raised against DOPA melanin from C. neoformans yeast cells (26). It is not clear whether the melanin produced by S. schenckii yeast cells grown in BHI medium is the L-DOPA or DHN melanin type. Previous data (25) indicated that S. schenckii conidia grown on potato dextrose agar synthesize melanin via the DHN pathway, and conidia from P. brasiliensis and H. capsulatum (7, 20) can also produce pigment when they are grown on minimal media, suggesting that the DHN pathway is involved in these situations as well. BHI medium is derived from the brains and hearts of cows, and these organs are rich in phenolic compounds that could serve as substrates for the production of DOPA melanin by S. schenckii yeast cells. However, it is interesting that yeast cells grown extensively in minimal medium were also able to produce a melanin-like pigment, presumably via the DHN pathway. The ability of S. schenckii yeast cells to produce melanin when they are grown in minimal medium indicates that these cells possess the enzymes necessary to synthesize precursors required for the formation of melanin in addition to any mechanism which utilizes exogenous phenolic compounds. There is good evidence of antigenic cross-reactivity between different melanin types; thus, MAb 6D2, which was raised against DOPA melanin from C. neoformans (26), is able to recognize the DHN melanin produced by conidia. We cannot be sure whether the novel MAbs which we produced were raised against DHN or DOPA melanin, but they were reactive with diverse melanins, including that from Aspergillus sp. (DHN melanin) and that from C. neoformans (DOPA melanin).
In summary, our results show that S. schenckii conidia and yeast cells synthesize melanin or melanin-like pigments in vitro and during infection. This raises the possibility that as in C. neoformans (2, 22) and E. dermatitidis (28), pigment production is linked to virulence in S. schenckii. Although the majority of sporotrichosis infections throughout the world are cutaneous or subcutaneous, spontaneous healing rarely occurs, and therefore treatment is almost always needed (3). Disseminated sporotrichosis is a recognized problem in AIDS patients, and these individuals require high doses of amphotericin B for many months and usually need secondary life-long prophylaxis (15). Melanization of C. neoformans decreases its susceptibility to amphotericin B (31, 32), and thus, formation of melanin or melanin-like compounds may add to the difficulty of treating some cases of sporotrichosis.
We thank H. Torres-Guerrero (Facultad de Medicina, Mexico City, Mexico) for supplying the Sporothrix melanin-deficient mutant Mel-14, Rosely M. Zancopé-Oliveira (Centro de Pesquisas Hospital Evandro Chagas, Fundacao Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil) for providing wild-type strain 16127, Soraya Diéz Posada (Corporacion para Investigaciones Biologicas, Medellin, Colombia) for supplying human sera from patients with sporotrichosis, and A. Robson (St. John's Institute of Dermatology) for dermatopathological support. We also thank Judith N. Steenbergen for help with transmission electron microscopy.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»